The New Role of Disodium Cromoglycate in the Treatment of Adults with Bronchial Asthma

DOI Web Site Web Site PubMed 被引用文献2件 参考文献62件
  • Miyatake Akihiko
    Miyatake Asthma Clinic
  • Fujita Mari
    Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine
  • Nagasaka Yukio
    Department of Respiratory Medicine, Sakai Hospital, Kinki University School of Medicine
  • Fujita Kimie
    School of Human Nursing, University of Shiga Prefecture
  • Tamari Mayumi
    Laboratory for Genetics of Allergic Diseases, Riken SNP Research Center
  • Watanabe Dai
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University School of Medicine
  • Nakano Naoko
    Department of Respiratory Medicine, Sakai Hospital, Kinki University School of Medicine
  • Hidari Kazuya I.P.J.
    Department of Biochemistry, University of Shizuoka, School of Pharmaceutical Sciences, CREST, JST
  • Suzuki Yasuo
    Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, CREST, JST

この論文をさがす

抄録

Background: Viral infection of the respiratory tract in patients with asthma is one of the most frequent causes of exacerbation of asthmatic symptoms. Disodium cromoglycate (DSCG) is a commonly used anti-asthmatic medicine with many beneficial biochemical and physiological effects. The purpose of this study was to investigate the efficacy of DSCG against colds when used in clinical practice.<br> Methods: A questionnaire survey to determine the efficacy of DSCG was undertaken in 220 adult patients with asthma (81 male, 139 female; mean age: 54.1 ± 13.7 years and 60.1 ± 12.7 years, respectively) from April to September 2004 at the Miyatake Asthma Clinic.<br> Results: The duration of DSCG inhalation therapy was not less than 5 years in more than half of the patients. The mean daily DSCG dose at the time of the questionnaire survey was 40mg/day in over 50% of all patients. After DSCG was added to inhaled corticosteroid (ICS) combination therapy, 56.4% of the patients rated their condition as "improved", and 66.4% of the patients felt that the frequency of colds they had caught had decreased while DSCG was added to ICS.<br> Conclusions: DSCG inhalation therapy is a useful additional treatment following ICS to alleviate asthma symptoms, and to prevent colds in adult patients with asthma.<br>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (62)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ